Cargando…
Enhanced tumor inhibiting effect of 131I-BDI-1-based radioimmunotherapy and cytosine deaminase gene therapy modulated by a radio-sensitive promoter in nude mice bearing bladder cancer
Radioimmunotherapy (RIT) has great potential in cancer therapy. However, its efficacy in numerous tumors is restricted due to myelotoxicity, thereby limiting the dose of radionuclide. To increase tumor radiosensitivity, we incorporated the recombinant lentivirus into the EJ cells (bladder cancer [BC...
Autores principales: | Hao, Pan, Zhang, Chunli, Ma, Huan, Wang, Rongfu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855308/ https://www.ncbi.nlm.nih.gov/pubmed/36418230 http://dx.doi.org/10.1093/jrr/rrac075 |
Ejemplares similares
-
Radioimmunotherapy for Pancreatic Carcinoma Using (131)I‐Labeled Monoclonal Antibody Nd2 in Xenografted Nude Mice
por: Inui, Akimasa, et al.
Publicado: (1996) -
Targeted radioimmunotherapy with the iodine-131-labeled caerin 1.1 peptide for human anaplastic thyroid cancer in nude mice
por: Lin, Ruoting, et al.
Publicado: (2021) -
Rhenium‐186‐mercaptoacetyltriglycine‐labeled Monoclonal Antibody for Radioimmunotherapy: In vitro Assessment, in vivo Kinetics and Dosimetry in Tumor‐bearing Nude Mice
por: Kinuya, Seigo, et al.
Publicado: (1998) -
Radioimmunotherapy with tositumomab and iodine-131 tositumomab for non-Hodgkin’s lymphoma
por: Andemariam, Biree, et al.
Publicado: (2007) -
Radioimmunotherapy study of (131)I-labeled Atezolizumab in preclinical models of colorectal cancer
por: Zhang, Linhan, et al.
Publicado: (2022)